Arcadia Biosciences (RKDA) Cost of Revenue (2014 - 2025)

Arcadia Biosciences has reported Cost of Revenue for 12 years, with the latest figure at $709000.0 in Q4 2025.

• For the quarter ending Q4 2025, Cost of Revenue fell 14.27% year-over-year to $709000.0; the trailing twelve-month figure through Dec 2025 stood at $3.1 million (up 4.59% YoY), and the FY2025 full-year result was $3.1 million, up 4.56% from the prior year.
• Cost of Revenue for Q4 2025 stood at $709000.0, down from $884000.0 in the prior quarter.
• The five-year high for Cost of Revenue was $3.8 million in Q4 2021, with the low at $178000.0 in Q4 2023.
• Historically, Cost of Revenue has averaged $1.3 million across 5 years, with a median of $841500.0 in 2021.
• Annual changes were most pronounced in 2021 — Cost of Revenue soared 548.48% — and 2023, when it tumbled 81.14%.
• Arcadia Biosciences' Cost of Revenue stood at $3.8 million in 2021, then sank by 76.03% to $900000.0 in 2022, then sank by 80.22% to $178000.0 in 2023, then surged by 364.61% to $827000.0 in 2024, then dropped by 14.27% to $709000.0 in 2025.
• The last three Cost of Revenue figures came in at $709000.0 (Q4 2025), $884000.0 (Q3 2025), and $824000.0 (Q2 2025), per Business Quant data.